Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Reid

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Gynecologic Oncology|June 25, 2005
Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group StudyHoward D Homesley, John A Blessing, Joel Sorosky, et al.
Gynecologic Oncology|July 9, 2014
Outcomes of patients with low-risk endometrial cancer surgically staged without lymphadenectomy based on intra-operative evaluationJeffrey G Bell, Diana M Patterson, Jennifer Klima, et al.
American Journal of Clinical Oncology|December 13, 2002
Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group studyRobert F Asbury, Virginia L Brunetto, Roger B Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyHolly H Gallion, Virginia L Brunetto, Michael Cibull, et al.
Gynecologic Oncology|August 29, 2009
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyCarol Aghajanian, John A Blessing, Kathleen M Darcy, et al.
Cancer Research|August 4, 2006
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patientsHeather Hampel, Wendy Frankel, Jenny Panescu, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Gynecologic Oncology|June 25, 2005
Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group StudyHoward D Homesley, John A Blessing, Joel Sorosky, et al.
Gynecologic Oncology|July 9, 2014
Outcomes of patients with low-risk endometrial cancer surgically staged without lymphadenectomy based on intra-operative evaluationJeffrey G Bell, Diana M Patterson, Jennifer Klima, et al.
American Journal of Clinical Oncology|December 13, 2002
Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group studyRobert F Asbury, Virginia L Brunetto, Roger B Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyHolly H Gallion, Virginia L Brunetto, Michael Cibull, et al.
Gynecologic Oncology|August 29, 2009
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyCarol Aghajanian, John A Blessing, Kathleen M Darcy, et al.
Cancer Research|August 4, 2006
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patientsHeather Hampel, Wendy Frankel, Jenny Panescu, et al.
Pageof 2